用于合理设计针对阿尔茨海默氏病的新型氧克林衍生物的计算建模
Mohamed El Fadili1, Mohammed Er-Rajy1, Somdutt Mujwar2
1LIMAS Laboratory, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
PloS one
|March 5, 2026
概括
这项研究探讨了用于阿尔茨海默氏症治疗的新型氧塔克林衍生物. 化合物D9-D12表现有前途,其中D9表现出稳定性和有利于药物开发的特性.
科学领域:
- 药用化学 医学化学
- 计算机化药物发现技术
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病是痴呆的主要原因,导致认知和行为衰退.
- 目前对阿尔茨海默病的治疗有局限性,需要开发新的治疗药物.
研究的目的:
- 识别新型的氧塔克林衍生物,对阿尔茨海默病有潜在的治疗益处.
- 为了建立一个定量结构-活性关系 (QSAR) 的细胞毒性作用的氧塔克林衍生物.
主要方法:
- 使用比较分子相似度指数分析和比较分子场分析开发和验证3D-QSAR模型.
- 基于经过验证的QSAR洞察力的新化合物的设计.
- 分子对接,分子动力学 (MD) 模拟和ADME-Tox分析以评估药理潜力.
主要成果:
- 四种化合物 (D9-D12) 显示出有利的药理动力学特性和高安全性.
- 化合物D9的细胞毒性较低 (pIC50=3.50),与太克林 (pIC50=3.52) 相比.
- MD模拟证实了D9与NMDA受体 (PDB ID: 5EWJ) 复合的异常热力学稳定性超过100个nS.
结论:
- 化合物D9-D12是进一步开发抗阿尔茨海默病药物的有希望的候选者.
- 这项研究为设计更有效,更安全的神经退行性疾病治疗剂提供了坚实的基础.
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
49
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
49
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
765
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
765
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
71
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
71


